Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
small molecule |
| gptkbp:administeredBy |
oral
|
| gptkbp:approvalYear |
2011
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01XE16
|
| gptkbp:bioavailability |
43%
|
| gptkbp:brand |
gptkb:Xalkori
|
| gptkbp:CASNumber |
877399-52-5
|
| gptkbp:chemicalFormula |
C21H22Cl2FN5O
|
| gptkbp:contraindication |
hypersensitivity
|
| gptkbp:developedBy |
gptkb:Pfizer
|
| https://www.w3.org/2000/01/rdf-schema#label |
crizotinib
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
gptkb:receptor_tyrosine_kinase
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
vomiting diarrhea edema constipation fatigue vision disorder |
| gptkbp:target |
gptkb:ALK
gptkb:MET ROS1 |
| gptkbp:usedFor |
gptkb:non-small_cell_lung_cancer
|
| gptkbp:bfsParent |
gptkb:ALK_rearrangement
|
| gptkbp:bfsLayer |
5
|